Potential therapy of multidrug-resistant and extremely drug-resistant tuberculosis with thioridazine.

Leonard Amaral, Joseph Molnar

Journal: In vivo (Athens, Greece) 2012;26(2):231-6

PMID: 22351663

Abstract

Multidrug-resistant tuberculosis (MDRTB) infections that continue to increase in frequency globally have progressed to become extremely drug-resistant tuberculosis (XDRTB). The therapeutic problems associated with MDRTB pale in comparison to those for XDRTB where mortality is high. This mini-review highlights the evidence that supports the use of the phenothiazine neuroleptic thioridazine for the therapy of XDRTB. Although thioridazine does produce some serious side-effects, the poor prognosis associated with an XDRTB infection of a patient that presents with AIDS merits that the use of thioridazine for therapy of XDRTB is seriously considered. A recommended protocol is presented.

Address: Group of Mycobacteriology, Unit of Medical Microbiology, Institute of Hygiene and Tropical Medicine, Universidade Nova de Lisboa, Lisbon, Portugal. [email protected]

Link outs

Subscription / membership required

Full Text Sources:

https://iv.iiarjournals.org/lookup/pmidlookup?view...

MeSH Terms: AIDS-Related Opportunistic Infections, Antitubercular Agents, Bacterial Proteins, Biological Availability, Calcium, Compassionate Use Trials, Extensively Drug-Resistant Tuberculosis, Heart Diseases, Humans, Ion Transport, Mycobacterium tuberculosis, Neuroleptic Malignant Syndrome, Phagosomes, Potassium, Prognosis, Protein Binding, Salvage Therapy, Thioridazine, Tuberculosis, Multidrug-Resistant, Tuberculosis, Pulmonary